Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
06 May 2020
06 May 2020
Historique:
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Emerging data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have largely been presented as case series. Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses. We examined all patients presenting to an emergency department in San Francisco, California between February 3 and March 31, 2020 with an acute respiratory illness who were tested for SARS-CoV-2. We determined COVID-19 status by PCR and metagenomic next generation sequencing (mNGS). We compared demographics, comorbidities, symptoms, vital signs, and laboratory results including viral diagnostics using PCR and mNGS. Among those hospitalized, we determined differences in treatment (antibiotics, antivirals, respiratory support) and outcomes (ICU admission, ICU interventions, acute respiratory distress syndrome, cardiac injury). In a cohort of 316 patients, 33 (10%) tested positive for SARS-CoV-2; 31 patients, all without COVID-19, tested positive for another respiratory virus (16%). Among patients with additional viral testing, no co-infections with SARS-CoV-2 were identified by PCR or mNGS. Patients with COVID-19 reported longer symptoms duration (median 7 vs. 3 days), and were more likely to report fever (82% vs. 44%), fatigue (85% vs. 50%), and myalgias (61% vs 27%); p<0.001 for all comparisons. Lymphopenia (55% vs 34%, p=0.018) and bilateral opacities on initial chest radiograph (55% vs. 24%, p=0.001) were more common in patients with COVID-19. Patients with COVID-19 were more often hospitalized (79% vs. 56%, p=0.014). Of 186 hospitalized patients, patients with COVID-19 had longer hospitalizations (median 10.7d vs. 4.7d, p<0.001) and were more likely to develop ARDS (23% vs. 3%, p<0.001). Most comorbidities, home medications, signs and symptoms, vital signs, laboratory results, treatment, and outcomes did not differ by COVID-19 status. While we found differences in clinical features of COVID-19 compared to other acute respiratory illnesses, there was significant overlap in presentation and comorbidities. Patients with COVID-19 were more likely to be admitted to the hospital, have longer hospitalizations and develop ARDS, and were unlikely to have co-existent viral infections. These findings enhance understanding of the clinical characteristics of COVID-19 in comparison to other acute respiratory illnesses. .
Sections du résumé
BACKGROUND
BACKGROUND
Emerging data on the clinical presentation, diagnostics, and outcomes of patients with COVID-19 have largely been presented as case series. Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses.
METHODS
METHODS
We examined all patients presenting to an emergency department in San Francisco, California between February 3 and March 31, 2020 with an acute respiratory illness who were tested for SARS-CoV-2. We determined COVID-19 status by PCR and metagenomic next generation sequencing (mNGS). We compared demographics, comorbidities, symptoms, vital signs, and laboratory results including viral diagnostics using PCR and mNGS. Among those hospitalized, we determined differences in treatment (antibiotics, antivirals, respiratory support) and outcomes (ICU admission, ICU interventions, acute respiratory distress syndrome, cardiac injury).
FINDINGS
RESULTS
In a cohort of 316 patients, 33 (10%) tested positive for SARS-CoV-2; 31 patients, all without COVID-19, tested positive for another respiratory virus (16%). Among patients with additional viral testing, no co-infections with SARS-CoV-2 were identified by PCR or mNGS. Patients with COVID-19 reported longer symptoms duration (median 7 vs. 3 days), and were more likely to report fever (82% vs. 44%), fatigue (85% vs. 50%), and myalgias (61% vs 27%); p<0.001 for all comparisons. Lymphopenia (55% vs 34%, p=0.018) and bilateral opacities on initial chest radiograph (55% vs. 24%, p=0.001) were more common in patients with COVID-19. Patients with COVID-19 were more often hospitalized (79% vs. 56%, p=0.014). Of 186 hospitalized patients, patients with COVID-19 had longer hospitalizations (median 10.7d vs. 4.7d, p<0.001) and were more likely to develop ARDS (23% vs. 3%, p<0.001). Most comorbidities, home medications, signs and symptoms, vital signs, laboratory results, treatment, and outcomes did not differ by COVID-19 status.
INTERPRETATION
CONCLUSIONS
While we found differences in clinical features of COVID-19 compared to other acute respiratory illnesses, there was significant overlap in presentation and comorbidities. Patients with COVID-19 were more likely to be admitted to the hospital, have longer hospitalizations and develop ARDS, and were unlikely to have co-existent viral infections. These findings enhance understanding of the clinical characteristics of COVID-19 in comparison to other acute respiratory illnesses. .
Identifiants
pubmed: 32511488
doi: 10.1101/2020.05.02.20082461
pmc: PMC7273256
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001870
Pays : United States
Organisme : NIAID NIH HHS
ID : R33 AI120977
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060530
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL138461
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL105704
Pays : United States
Références
JAMA. 2020 Apr 15;:
pubmed: 32293646
JAMA Cardiol. 2020 Mar 27;:
pubmed: 32219356
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32176772
JAMA. 2020 Mar 23;:
pubmed: 32203977
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Chem Lab Med. 2020 Apr 16;:
pubmed: 32301746
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Genome Res. 2014 Jul;24(7):1180-92
pubmed: 24899342
Eur J Intern Med. 2020 May;75:107-108
pubmed: 32192856
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12353-E12362
pubmed: 30482864
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
JAMA. 2020 Mar 3;:
pubmed: 32125362
JAMA. 2020 Apr 24;:
pubmed: 32329797
Clin Infect Dis. 2020 Mar 12;:
pubmed: 32161968
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
JAMA. 2020 Apr 6;:
pubmed: 32250385
Sci China Life Sci. 2020 Apr;63(4):606-609
pubmed: 32170625
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Nat Microbiol. 2020 Mar;5(3):443-454
pubmed: 31932713
Clin Infect Dis. 2020 Feb 29;:
pubmed: 32109279
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
JAMA Cardiol. 2020 Mar 25;:
pubmed: 32211816
JAMA. 2020 Feb 7;:
pubmed: 32031570
JAMA. 2020 Apr 22;:
pubmed: 32320003
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
JAMA. 2020 Mar 31;:
pubmed: 32232421
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
mBio. 2019 Dec 17;10(6):
pubmed: 31848287
J Med Virol. 2020 Apr 20;:
pubmed: 32311094
Clin Infect Dis. 2020 Mar 25;:
pubmed: 32211755
PLoS One. 2019 Jan 10;14(1):e0206194
pubmed: 30629604
Eur Radiol. 2020 Apr 16;:
pubmed: 32300971
JAMA. 2020 Mar 19;:
pubmed: 32191259
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32173725
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Clin Chim Acta. 2020 Aug;507:94-97
pubmed: 32315614